Valion Bio, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price
Valion Bio, Inc. (VBIO) had Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price of $22.63 per share as of 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice · last filed 2026-08-14
- 2026-06-30: Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price $22.63.
- 2026-03-31: Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price $24.45.
- 2025-09-30: Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price $259.70.
- 2025-06-30: Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price $346.95.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price |
|---|---|
| 2026-06-30 | $22.63 10-Q · filed 2026-08-14 |
| 2026-03-31 | $24.45 10-Q · filed 2026-05-14 |
| 2025-09-30 | $259.70 10-Q · filed 2025-11-14 |
| 2025-06-30 | $346.95 10-Q · filed 2025-08-14 |
| 2025-03-31 | $408.86 10-Q · filed 2025-05-15 |
| 2024-09-30 | $150.22 10-Q · filed 2024-11-14 |
| 2024-06-30 | $169.76 10-Q · filed 2024-08-14 |
| 2024-03-31 | $200.07 10-Q · filed 2024-05-15 |
| 2023-09-30 | $194.07 10-Q · filed 2023-11-14 |
| 2023-06-30 | $1.89 10-Q · filed 2023-08-14 |
| 2023-03-31 | $1.87 10-Q · filed 2023-05-15 |
| 2022-09-30 | $0.62 10-Q · filed 2022-11-14 |
| 2022-06-30 | $0.68 10-Q · filed 2022-08-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |